R&D Center
PCG-BIOTECH aims to develop innovative anticancer drugs with fewer side effects.
Pipeline
| Indication | Pipeline | Platform | Development Stage | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Target Validation |
Discovery (Hit to Lead) |
Lead Optimization |
PreClinical Development |
IND enabling |
PhaseⅠ | PhaseⅡ | PhaseⅢ | |||
| Acute Myeloid Leukemia (AML) |
PCG-C001 (First-in-Class) |
Chemical |  |
 |
||||||
| Metastatic Triple-Negative Breast Cancer (TNBC) |
PCG-C002 (First-in-Class) |
Ab/ADC |  |
|||||||
| PCG-C003 (First-in-Class) |
Chemical |  |
||||||||
| Metastatic Colorectal Cancer (CC) |
PCG-C004 (First-in-Class) |
Ab/ADC |  |
|||||||
| Huntington's disease (HD) |
PCG-N001 (First-in-Class) |
Chemical |  |
|||||||
| Small Cell Lung Cancer (SCLC) |
PCG-C005 (First-in-Class) |
Ab/ Chemical |
 |
|||||||
| Liver Cancer (LC) |
PCG-C006 (First-in-Class) |
Ab/ADC |  |
|||||||
| Bipolar Disorder (ND) |
PCG-N002 (First-in-Class) |
Chemical |  |
|||||||
| Degenerative Diseases (AD, PD) |
PCG-N003 (First-in-Class) |
Ab/ADC |  |
|||||||